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Abstract
The possibility of HIV-1 eradication has been limited by the existence of latently infected cellular reservoirs. Studies to
examine control of HIV latency and potential reactivation have been hindered by the small numbers of latently infected cells
found in vivo. Major conceptual leaps have been facilitated by the use of latently infected T cell lines and primary cells.
However, notable differences exist among cell model systems. Furthermore, screening efforts in specific cell models have
identified drug candidates for ‘‘anti-latency’’ therapy, which often fail to reactivate HIV uniformly across different models.
Therefore, the activity of a given drug candidate, demonstrated in a particular cellular model, cannot reliably predict its
activity in other cell model systems or in infected patient cells, tested ex vivo. This situation represents a critical knowledge
gap that adversely affects our ability to identify promising treatment compounds and hinders the advancement of drug
testing into relevant animal models and clinical trials. To begin to understand the biological characteristics that are inherent
to each HIV-1 latency model, we compared the response properties of five primary T cell models, four J-Lat cell models and
those obtained with a viral outgrowth assay using patient-derived infected cells. A panel of thirteen stimuli that are known
to reactivate HIV by defined mechanisms of action was selected and tested in parallel in all models. Our results indicate that
no single in vitro cell model alone is able to capture accurately the ex vivo response characteristics of latently infected T cells
from patients. Most cell models demonstrated that sensitivity to HIV reactivation was skewed toward or against specific
drug classes. Protein kinase C agonists and PHA reactivated latent HIV uniformly across models, although drugs in most
other classes did not.
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Introduction
The possibility to achieve HIV eradication has been limited, at
least in part, by the existence of latently infected cellular reservoirs
[1–3]. The major known cellular reservoir is established in
quiescent memory CD4+ T cells, providing an extremely long-
lived set of cells in which the virus can remain transcriptionally
silent [1–3]. Reactivation of latent viruses followed by killing of the
infected cells has been proposed as a possible strategy (‘‘shock and
kill’’) to purge the latent reservoir [4].
Studies to examine the control of HIV latency and potential
reactivation have been hindered, however, by the small numbers of
latently infected cells in vivo and the absence of known phenotypic
markers that can distinguish them from uninfected cells. In this
setting, cell-line models of latency have been very useful due to their
genetic and experimental tractability. Major conceptual leaps have
been facilitated by the use of latently infected T cell lines [5–10],
including the ability to conduct genetic screens [11]. On the other
hand, latently infected cell lines are limited by their cycling nature
and inherent mutation in growth controls, and the clonal nature of
the virus integration sites. Such transformed cell lines lack the
ability to differentiate and naturally oscillate between phases of
quiescence and active proliferation in response to biological signals.
Because of these limitations, a number of laboratories have recently
developed primary cellular models of HIV-1 latency that capitalize
on specific aspects of the T cell reservoir, found in vivo (reviewed in
references [12–14]). These newer models afford investigators the
ability to easily and rapidly study proposed mechanisms governing
latency and to evaluate novel small molecule compounds for
induction of viral reactivation.
One significant complication, associated with the present variety
of available latency models, is that notable differences exist among
the cell model systems. Disparities relate to: the T-cell subsets
being represented; the cellular signaling pathways that are capable
of driving viral reactivation; and the genetic composition of the
viruses employed, ranging from wild-type to functional deletion of
multiple genes. Additional differences reside in the experimental
approaches taken to establish latent infection in these primary cell
models, which involve either infection of activated cycling cells
that are later allowed to return to a resting state [15–19], or direct
infection of quiescent cells [20,21]. Because of such system
variables, screening efforts in specific cell models with identified
drug candidates for ‘‘anti-latency’’ therapy often fail to reactivate
HIV uniformly across the different models. Therefore, the activity
of a given drug candidate, demonstrated in a particular cellular
model, cannot predict reliably the activity that will be seen in other
cell model systems or in infected patient cells, tested ex vivo. The
current situation in this research field represents a critical
knowledge gap that is adversely affecting our ability to identify
promising treatment compounds and their associated molecular
mechanisms and is hindering the advancement of drug testing into
relevant animal models and ultimately, human clinical trials.
The present work represents a broad collaborative effort to
compare and contrast induction of HIV reactivation across a
battery of well-characterized cell models of viral latency,
employing a highly coordinated and standardized testing ap-
proach. This work is based on the premise that it is unlikely that a
single in vitro cell model can completely recapitulate the biological
properties of the latent reservoir in vivo, let alone reflect accurately
the response characteristics of infected patient cells ex vivo.
Therefore, it is important to define both the common and unique
properties among the available cell models of HIV latency in order
to design a rational approach to employ such models in the
identification of valid candidate drugs to induce HIV reactivation.
Examples of how such an approach also can inform the
underlying mechanistic actions of experimental compounds are
available in the field. For instance, in the latency model developed
by Bosque et al. [15], the derived central memory CD4+ T cells
(TCM) are highly responsive to stimuli that activate the nuclear
factor of activated T-cells (NFAT); on the other hand, virus
reactivation from J-Lat clones [8] tends to be highly responsive to
stimuli that activate the nuclear factor kappa of B cells (NFkB),
such as protein kinase C (PKC) activators and tumor necrosis
factor-alpha (TNF-a). Although the use of these two model systems
would predictably yield different types of hits during a compound
library screen, it is important to note that known compounds,
which signal through either of these activation pathways, are
capable of reactivating HIV replication in latently infected CD4+
T cells from patients ex vivo, and by inference, perhaps in vivo.
To begin to understand the biological characteristics that are
inherent to each model of HIV-1 latency, we compared the
properties of six models (Table 1), to those obtained with a
standard viral outgrowth assay using patient-derived infected cells
[1,22]. As no specific denominations have been assigned to these
models, we have for simplicity referred to them by the name of the
senior investigator in whose laboratory they were developed. They
included the following (details are provided within the Methods
section):
The Greene laboratory model [23] is a modification of the
original O’Doherty model of latency [20] and establishes HIV
infection directly in quiescent primary CD4+ cells, using
spinoculation delivery of virus. Replication-competent NL4-3
reporter virus is used, which contains Luciferase in the nef reading
frame (Dnef/luciferase). After a short 3 day-culture, induction of
provirus activation from latency is performed in the presence of
integrase inhibitor to prevent viral spread and the contribution
of any unintegrated viral species. Quantification of HIV replica-
tion by Luciferase expression is population-based. While only
approximately 5–10% of the culture contains latently infected
cells, this assay permits the generation and analysis of test
compounds within 6 days.
The model developed by Lewin and colleagues uses exposure of
primary resting CD4+ T cells to chemokines that bind to receptors
CCR7, CXCR3 or CCR6 to effectively establish infection with
wild-type NL4-3 virus [21,24]. Incubation with the chemokines
does not cause significant cellular activation, but induces changes
in the cellular actin cytoskeleton, which allows for efficient virus
nuclear localization, integration, and establishment of latent
infection [24]. Treatments to reactivate virus are followed by
Author Summary
HIV establishes a state of latency in vivo and this latent
reservoir, although small, is difficult to eradicate. To be
able to better understand this state of latency, and to
develop strategies to eliminate it, many groups have
developed in vitro models of HIV latency. However,
notable differences exist among cell model systems
because compounds that reactivate latent HIV in a
particular system often fail to do so uniformly across
different models. To begin to understand the biological
characteristics that are inherent to each HIV model of
latency, we compared the response properties of five
primary T cell, four J-Lat cell models and those obtained
with patient-derived infected cells. A panel of thirteen
stimuli that are known to reactivate HIV by defined
mechanisms of action was selected and tested in parallel in
all models.
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co-culture with amplifying feeder cells. Productive HIV replication
is determined on a total population basis by quantification of
soluble reverse transcriptase (RT) activity released into culture.
The Planelles model [14,15] establishes viral latency in cultured
primary CD4+ T cells that have been differentiated by TCR
stimulation in the presence of TGF-b, and aIL-4 and aIL-12
monoclonal antibodies into a non-polarized subset, representative
of central memory cells (TCM) [14,25]. Spinoculation with a
packaged env defective NL4-3 clone establishes a single round of
infection in the majority of the cells that transition into latency.
Induced reactivation of HIV is monitored on a per-cell basis, using
staining and flow cytometry detection for intracellular Gag (p24)
expression.
The Siliciano model [17] uses a two-step derivation of latency in
cultured primary CD4+T cells, isolated from peripheral blood. In
the first step, cells are TCR stimulated, transduced with the EB-
FLV lentiviral vector, for constitutive expression of Bcl-2,
expanded in culture with IL-2 and allowed to return to a resting
state. In the second step, the cells are reactivated and infected with
a trans-packaged, replication defective NL4-3 GFP-reporter virus
clone (NL4-3-D6-drEGFP). After 3–4 weeks of culture, the GFP-
negative cell subset, expressing a quiescent effector memory cell
(TEM) phenotype, is isolated by flow cytometry sorting. Approx-
imately, 2–6% of the recovered cells carry latent HIV infection.
Reactivation of virus replication is tracked by GFP expression, on
an individual cell basis.
The Spina model (unpublished results; manuscript submitted) is
based on early work demonstrating that HIV-1 can establish
infection directly in resting primary CD4+ T lymphocytes in vitro
[26,27], and on recent work showing that during acute HIV
infection in a heterogeneous population of primary CD4+ T cells,
undergoing varying degrees of cell activation, viral latency is
established early and preferentially in non-dividing and minimally
activated cells. This model uses the experimental approach of
deriving latent NL4-3 infection (wild-type) in non-dividing
‘‘bystander’’ cells during brief co-culture with autologous produc-
tively infected, proliferating cells. When the quiescent bystander
cell population is isolated from co-culture, the latently infected
subset ranges from 1 to 12% cells containing integrated HIV
DNA, and 0.5–5% cells with inducible provirus, as measured by
expression of intracellular Gag. Latent infection is found in all of
the major phenotypic subsets of T cells: naı̈ve, central memory and
effector memory. After incubations with experimental compounds,
reactivation of virus replication is measured on a population basis,
through quantification of tat mRNA by RT-qPCR.
Verdin and colleagues have generated a number of Jurkat cell
line-derived clones, bearing latent HIV-1 in single integration sites,
that were engineered to express GFP in lieu of nef [8] (J-Lat). J-Lat
cells have been used in numerous studies that have contributed a
wealth of knowledge in the area of viral latency. In contrast to
several other models of HIV latency in cell lines, where mutations
are present in the HIV tat gene or the TAR element, the J-Lat cell
model contains wild-type tat and TAR. Three J-Lat clones
established in the Verdin laboratory, 6.3, 8.4, 11.1 and one clone
generated by the Greene laboratory, 5A8, have been included in
this comparison. J-Lat 5A8 was derived by specifically selecting for
cells that would be more responsive to aCD3/aCD28 co-
stimulation than the parental J-Lat line [28]. Under untreated
basal conditions, little or no GFP expression is detected. However,
reactivation of latent provirus is readily monitored by flow
cytometry analysis of GFP expression.
Results obtained with the above cell models were compared to
results obtained in quantitative viral outgrowth assays (QVOA;
patient cell assay) performed in the Margolis laboratory, with
resting CD4+ T cells obtained from the leukopheresed peripheral
blood of aviremic, ART-treated HIV-infected patients. This assay,
as first described by three laboratories [1–3], was later modified to
its present design [22]. Following negative selection, resting CD4+
T cells are incubated with integrase and reverse transcriptase
inhibitors to ensure the decay of any HIV genomes in the state of
pre-integration latency [29]. The cells are exposed briefly to test
compounds, and then plated in replicate microwells in a terminal-
dilution assay and cultured with PHA-stimulated, allogeneic
irradiated peripheral blood mononuclear cells (PBMC) from a
sero-negative donor, and rIL-2. After 19 days, the microcultures
are scored for virus replication by soluble p24 production, and the
number of cells containing replication-competent HIV is ex-
pressed as infectious units per million CD4+ T cells (IUPM).
Induction of viral reactivation across all cell models was assessed
using a selected common panel of stimuli that are known to
function by distinct and defined mechanisms of action. The panel
included 13 treatments (Table 2) that modulate T cell processes
such as T-cell receptor engagement, protein kinase C (PKC)
activation, calcium influx, cytokine signaling, histone deacetyla-
tion, and release of P-TEFb from the HEXIM/7SK RNP
complex. This study was designed to answer the following
Table 1. Properties of the models used in this study.
Model/Cell type Source of T-cells
Cell cycle status
upon infection Phenotype during latency Virus/vector
Readout upon
reactivation





NL4-3 (WT) Soluble RT activity
Patient Cells/QVOA Primary, resting
CD4+ T-cells from
infected patients
NA CD252/DR2 Endogenous IUPM (limiting dilution)
Planelles Primary naı̈ve CD4+
T-cells




%GFP+ or % IC-Gag+
cells
Siliciano Primary CD4+ T-cells Dividing CD45RO+, CD62L+ CCR72 NL4-3D6-drEGFP % GFP+ cells
Spina Primary CD4+ T cells Resting Mixture of TN, Tcm, TEM, TE HIV-1 NL4-3 (WT) Tat mRNA copies
Verdin Jurkat-derived clones Dividing NA HIV-1 R7 (GFP) % GFP+ cells
TCM: CCR7+, CD27+, CD45RO+, CD25low CD692; TTM: CCR72, CD27+, CD45RO+, CD25low CD692; TN: CCR7+, CD27+, CD45RO2; TEM: CCR72, CD272, CD45RO+.
doi:10.1371/journal.ppat.1003834.t001
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questions: 1) are certain models of latency biased towards or
against particular cell signaling pathways; 2) can stimuli be
identified that work uniformly in multiple models; 3) can a central
uniting theme or a single signaling pathway be responsible for
control of viral latency; and 4) can a model or limited group of
models predict experimental drug activity in authentic latently
infected cells from patients?
Results
Thirteen stimuli shown in Table 2 were chosen on the basis of
their known or proposed activities in reactivating latent HIV-1 in
various systems. For primary cell assays, experiments were
performed with cells from three different donors, and replicate
samples (duplicate or triplicate) were used for each treatment
variable tested (refer to Methods Section for details). For J-Lat
clones, experiments were performed in triplicate for each clone.
Figure 1, panels A and B depict the average responses (mean +/2
SEM) obtained with each of the cell models and the patient cell
outgrowth assay. In all cases, the stimulus providing maximal
reactivation response was used as a reference and assigned a 100%
value, and the results from all other stimuli were normalized as a
percentage of the maximal response (Figure 1). Within each
individual experiment (e.g., donor cells), the untreated baseline
value was first subtracted from each treatment response value,
prior to the normalization step. The average relative response was
then calculated across all experiments (donors) for each stimulus
tested. While transformed and primary cell models could be tested
at three concentrations of each stimulus, assays with patient cells/
QVOA were only performed at a single drug concentration due to
limiting cell numbers. Therefore, two comparisons were per-
formed: one which included all concentration points for each drug,
and did not include patient cell assay data; and a second one in
which a single concentration point was considered, to provide an
analysis that could include patient cell results.
The maximal response for all primary models, except for the
Lewin model and the patient-cell outgrowth assay, was obtained
with aCD3+aCD28 antibody stimulation. In the Lewin model and
the QVOA, PHA was the stimulus yielding a maximal response.
The maximal response in the four J-Lat clones was obtained with
PMA+Ionomycin. In all the J-Lat clones, except 5A8, CD3 surface
expression is normally downregulated in culture (E.V., W.C.G.,
unpublished data). CD3 downregulation makes these cells
unresponsive to aCD3/aCD28 antibody stimulation, although
they remain responsive to PHA (most likely through engagement
of the CD2 receptor). An additional representation of the data is
shown in Figure S1, where, for each treatment, only the
concentration of compound that was most active is represented.
T-cell receptor engagement
T-cell receptor engagement is effectively mimicked by the
binding and cross-linking of antibodies against CD3e, one of the
signal transduction subunits in the CD3 complex [30] and the co-
stimulatory molecule, CD28 [31].
Phytohemagglutinin (PHA-M) is a lectin that binds to carbo-
hydrate moieties on surface glycoproteins. PHA is a polyclonal
mitogen for T cells. Both PHA and aCD3/aCD28 antibody
treatments stimulate signaling cascades that encompass TCR/
LCK/p38 activation leading to calcineurin and NFAT activation,
as well as PKC stimulation leading to NFkB activation. Incubation
with aCD3/aCD28 antibody-coated beads produced strong
responses in all primary cell models, with the exception of the
Lewin model (Figure 1A). In contrast, all J-Lat clones, except 5A8
were completely unresponsive to aCD3+aCD28 incubation
(Figure 1B). The response of J-Lat 5A8 cells after stimulation by
aCD3+aCD28 coated beads, although detectable, was lower than
that displayed by most primary cell models. However, the levels of
stimulation can be improved using plate-bound aCD3 and free
aCD28 antibodies, if so desired (D.R. and W.C.G., data not
shown). Moreover, these cells are highly responsive to PHA, which
indicates that these cells contain an intact signaling pathway
downstream of TCR engagement.
PHA reactivated latent viruses in all primary cell models and in
the J-Lat clones, although with variable efficiency (Figure 1,
Panels A and B). Therefore, the lack of responsiveness of J-Lat
clones and of cells in the Lewin model to aCD3+aCD28
antibody treatment cannot be attributed to a lack of signaling
mediators, since these cells respond to PHA through a highly
similar signaling pathway.
Activation through protein kinase C
PKC is a family of ten kinases that are activated by phorbol
esters [32]. In general, phorbol esters promote activation and
differentiation of monocytes and monocytoid cells, as well as
potent T-cell activation. Three PKC agonists were tested, namely
PMA, prostratin (both phorbol esters); and bryostatin-1 (a cyclic
polyketide). PKC agonists activate the DAG-PKC-NFkB signaling
pathway. PMA has long been used as a T-cell mitogen. PMA was
tested at 2 nM in primary cell models and 16 nM in J-Lat clones.
At these concentrations, PMA elicited maximal or near-maximal
responses in J-Lat cells, except in clone 8.4. Responses to PMA
were near maximal in the Planelles and Siliciano models; the rest
Table 2. List of stimuli used in this study and their corresponding signaling pathways.
Stimulus Physiologic Activity Signaling Axis
aCD3+aCD28 PHA TCR engagement Lck/Calcineurin/NFAT and PKC/NFkB
PMA Prostratin Bryostatin PKC activation PKC/NFkB and PKC/MAPK
PMA+Iono. PKC activation and Ca++ influx PKC/NFkB; PKC/MAPK and calcineurin
TNF-a TRAF recruitment NFkB/AP-1
IL-7+IL-2 cc-receptor engagement JAK/STAT and PI3K/AKT/NFkB
SAHA MRK-1 MRK-11 HDAC inhibition Chromatin remodeling and activation of transcription (not gene-
specific)
HMBA Dissociation of P-TEFb from 7SK-RNP P-TEFb (not gene specific)
Ionomycin Ca++ influx Calcineurin
doi:10.1371/journal.ppat.1003834.t002
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Figure 1. Graphic summary of the ability of each compound to activate HIV within each cell model: (A) primary CD4 T cell models
and patient cell outgrowth assay (QVOA), and (B) J-Lat T cell line clones. Each compound and concentration tested is listed on the X-axis. In
the primary CD4 cell models, each compound was tested using cells from 2, 3 or 4 different donors and in duplicate or triplicate with cells from each
donor (See Methods Section for details). For the QVOA, results from the limiting dilution cultures from 3 patients were pooled to calculate one
Comparison of HIV-1 Latency Model Systems
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of the primary cell models and the QVOA also showed viral
reactivation in response to PMA, although at more modest levels.
Prostratin is a unique phorbol ester in that it induces potent T
cell activation signals but, unlike PMA, is not tumorigenic. The
ability of prostratin to induce T-cell activation through PKC,
without tumor promoting ability, has made prostratin the subject
of studies for its possible use as an inductive adjuvant therapy in
the context of anti-retroviral therapy (ART) [33]. Another unique
property of prostratin is that, despite being able to reactivate latent
HIV-1, it exerts an inhibitory effect on active HIV-1 replication
through downregulation of CD4 [34,35]. The relative reactivation
efficiencies observed in response to prostratin were similar to those
obtained with PMA treatment. Thus, the models with the highest
responses to PMA (J-Lat 6.3 and 11.1 clones, and Siliciano and
Planelles models) showed the highest responses to prostratin as
well. Conversely, poor to intermediate responses to PMA,
observed in the Greene, Lewin and Spina models, and the
quantitative patient-cell outgrowth assay (QVOA) were paralleled
by similar responses to prostratin (Figure 1, Panels A and B). In the
specific case of the Greene model, it has been observed that only a
minority of cells, about 5%, respond to PMA, although the reasons
for this observation are unknown.
Bryostatins are a family of natural products found in several
species of bryozoans. Bacterial symbionts of the bryozoan species
are thought to be responsible for bryostatin synthesis (reviewed in
[36]). Bryostatins bind to the diacylglycerol-binding region within
the C-1 regulatory domain of PKC. Bryostatin-1 was recently
shown to reactivate latent HIV-1 in vitro in monocytoid and
lymphoid cell line models of latency [37] and was approximately
1,000-fold more potent than prostratin. More recently, DeChris-
topher and colleagues achieved the chemical synthesis of several
analogs of bryostatin-1, which demonstrated potent activity in J-
Lat cells [38]. Bryostatin-1 was very potent in J-Lat clone 11.1, but
had only modest activity in the other J-Lat clones (Figure 1B). In
primary cell models, bryostatin-1 induced maximal response in the
Siliciano model, and about half-maximal responses in the Lewin
and Planelles models. However, the Greene and Spina models,
and the patient cell outgrowth assay, showed very low to non-
detectable responses to bryostatin-1 (Figure 1A).
PKC stimulation in combination with a calcium
ionophore
A commonly utilized T-cell activation regimen in the labora-
tory, which mimics the signaling pathway used in TCR
engagement, is the combination of PKC activation via PMA
along with the calcium ionophore, Ionomycin, which bypasses the
requirement for both CD3/TCR and CD28 receptor engage-
ments. Signaling downstream of TCR engagement involves the
formation of inositol triphosphate, which triggers an increase in
the intracellular Ca2+ concentrations, which in turn activate the
phosphatase, calcineurin. Calcineurin then dephosphorylates
cytoplasmic NFAT transcription factor, which translocates to the
nucleus. A combination of PMA and Ionomycin induced vigorous
viral reactivation in most cell models tested, but not in the Spina
model. Viral reactivation in response to PMA+Ionomycin was
generally increased when compared to that of PMA alone, with
the exception of the Lewin and Spina models (Figure 1, panels A
and B). Unexpectedly, PMA+Ionomycin stimulation of primary T-
cells in the Spina model caused inhibition of Tat mRNA
transcription, the readout in this assay, to below initial basal
levels (Figure 1A). It has been reported previously that PMA
induction of HIV replication can be Tat-independent [39]; and in
this case, the combination with Ionomycin appeared to actually
suppress Tat transcription at 24 hrs. following stimulation. In the
patient cell outgrowth assay/QVOA, PMA+Ionomycin produced
a strong reactivation response that was higher than that observed
with each compound alone.
Cytokine stimulation
Previous reports showed that incubation with IL-7, alone [40]
or in combination with IL-2 [41] can reactivate latent HIV-1 in
resting CD4+ T cells isolated from infected individuals. IL-7 also
reactivated latent HIV-1 in thymocytes in a SCID-hu mouse
model of HIV latency [42] and in cultured TCM in the Planelles
model [43]. In the Planelles model, IL-2+IL-7 stimulation of
latently infected cells was previously shown to be inefficient (10–
20% of the reactivation obtained with aCD3/aCD28) and to
promote division of infected cells in the absence of viral
reactivation [43]. Responsiveness to IL-7, or IL-2+IL-7 stimula-
tion is physiologically relevant as these cytokines, along with IL-15,
are known to drive the homeostatic proliferation of memory T
cells in vivo [44]. A recent study found that IL-7, when
administered to HIV-1 infected patients undergoing ART,
promotes viral persistence by enhancing residual levels of viral
production and inducing proliferation of latently infected cells
without reactivation [45]. Robust responsiveness to IL-2+IL-7 was
observed in the Siliciano and Spina primary cell models, and
minimal activity was observed in the Greene model. Cells in the
Lewin and Planelles models and the patient cell outgrowth assay
responded poorly or not at all (,5% of maximal); whereas, cells in
the Greene model exhibited a weak response. It is interesting to
note that IL-7 used alone at 25 ng/ml induced robust reactivation
in the Lewin model [46]. J-Lat cells failed to reactivate virus in
response to IL-2+IL-7 stimulation. Jurkat cells, the parental tumor
cell line from which J-Lat clones were derived, are IL-2-
independent for their growth and survival, do not express the
high-affinity IL-2 receptor, CD25 [47,48], and express low levels
of the IL-7 receptor alpha [49].
TNF-a is a potent inducer of viral gene expression in certain
tumor cell lines harboring integrated, latent HIV-1, through the
activation of NFkB [5,8,50,51]. As previously reported, TNF-a
treatment activated virus expression in J-Lat cells, especially in
clones 6.3 and 11.1 (Figure 1B). However, among the primary cell
models, TNF-a failed to induce any detectable viral reactivation in
the Greene and Planelles models and showed only minimal
activity in the Lewin and Siliciano models. In contrast, the patient
cell outgrowth assay responded robustly to TNF-a, and cells in the
Spina model showed an intermediate response.
In order to better understand the responsiveness, or lack
thereof, to TNF-a, we analyzed the levels of TNF-R in primary
and Jurkat cells. We isolated bulk PBMC from two donors,
selected memory CD4+ cells using CD45RO expression, and then
stained the cells for CCR7, CD27 and the TNF-a receptor. These
experiments showed that none of the freshly selected memory
subsets tested (specifically, TCM, TEM and transitional memory T
cells, TTM) expressed detectable levels of the TNF-a receptor
(Figure S2). TNF-R expression was extremely low in cultured TCM
from the Planelles model (Figure S2). In contrast, J-Lat 10.6 cells
common IUPM (infectious units per million cells) value which was then normalized to that obtained with PHA. With the J-Lat clones, experiments
were performed in triplicate. Asterisks represent ‘‘not done’’.
doi:10.1371/journal.ppat.1003834.g001
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expressed high levels of TNF-R (Figure S2). HIV reactivation in
response to TNF-a in vitro and in vivo is likely linked to whether
cells under the specific culture or physiological conditions
upregulate the expression of the TNF-a receptor.
HMBA
Hexamethylene bisacetamide (HMBA) is a hybrid bipolar
compound that induces differentiation and apoptosis in trans-
formed cell lines in culture [52,53]. HMBA was shown to activate
HIV transcription in vitro [7,54], to reactivate latent HIV in vitro
[19,55] and to reactivate HIV in primary cells from aviremic,
infected patients [56]. The activity of HMBA on HIV transcrip-
tion is a result of its ability to induce dissociation of P-TEFb from
the inhibitory 7SK ribonucleoprotein complex [19,55].
HMBA treatment had significant reactivation activity in the
QVOA and the Lewin model, but demonstrated little to no
activity in the rest of the primary cell models and J-Lat clones
tested (Figure 1, panels A and B).
Histone deacetylase inhibitors
The ‘‘histone code’’ model states that a variety of covalent, post-
translational modifications (PTM) on histone tail residues regulate
the interaction of transcriptional regulators with chromatin to
determine gene expression levels. The nature and localization of
such post-translational modifications is broad, and their ability to
act in a combinatorial manner provides an attractive model for
how a finely tuned regulation can be effected. Histone code
modifications include acetylation, phosphorylation, methylation,
ubiquitination and sumoylation, among others [57,58]. Acetyla-
tion of lysine residues in histone tails can have two important
effects on chromatin organization (reviewed in [58]). First, this
PTM results in neutralization of a basic charge on the lysine
residue, which results in disruption of histone contacts with other
histones and with DNA, diminishing the degree of compaction of
the local chromatin. Second, proteins containing a specialized
domain known as bromodomain specifically recognize acetylated
lysine residues and then trigger downstream regulatory effects.
Acetylation of histones is regulated by the concerted action of
HATs and HDACs. Acetylated histones have long been associated
with actively transcribed genes [59] and, therefore, inhibitors of
HDAC (HDACi) are considered as general activators of
transcription. Two main categories of HDACs have been
described: Class I (HDAC 1, 2, 3 and 8), and Class II (HDAC
4, 5, 6, 7, 9, 10 and 11). Inhibition of Class I, but not Class II,
HDACs has been shown to induce reactivation of latent HIV
[60,61].
Suberoylanilide hydroxamic acid (SAHA; also known as
vorinostat) is a pan-HDAC inhibitor that targets both Class I
and Class II HDACs, and can induce reactivation of HIV in
models of HIV latency [11,62–65], and in resting cells from ART-
treated, aviremic HIV-infected patients [65–67], although it failed
to induce reactivation in patient cells in another study [68].
Recently, a single administration of SAHA to ART-treated,
aviremic patients was shown to induce global cellular acetylation
and increases in viral RNA in resting CD4+ cells from these
patients [69].
To test the ability of HDAC inhibitors to reactivate latent HIV
in the various models of latency, we utilized three such inhibitors,
provided by Merck Research Laboratories. SAHA potently blocks
the Class I HDACs (i.e., 1, 2, 3, and 8) and has modest activity
against Class II HDACs (i.e., 6, 10 and 11). MRK-1 is a selective
inhibitor of the Class I HDACs (i.e., 1, 2 and 3) and HDAC6 (Class
II); whereas, MRK-11 selectively blocks Class II HDACs (i.e., 4, 5,
6 and 7) and HDAC8 (Class I) [60].
SAHA was moderately potent in the Lewin and Spina cell
models and QVOA, but was marginally active or inactive in the
rest of the primary cell models and the J-Lat clones. The activity
profile of MRK-1 was similar to that of SAHA in the primary
models, showing the best activity in the Lewin cell model and the
patient cell outgrowth assay. All the J-Lat clones had modest
responses to MRK-1, which contrasted with the poor activity seen
with SAHA in these cells (Figure 1B). The differences between
SAHA and MRK-1 responses could, potentially be explained by
the slightly different specificities of these HDAC inhibitors.
In general, MRK-11 was inactive or minimally active (,20%
response) in the QVOA and all J-Lat and primary cell models,
except in the Lewin model, where it exhibited close to 50%
activity. Cells in the Lewin model are unique in this study, in that
they are very sensitive to viral reactivation by both Class I and
Class II HDAC inhibitors. In contrast, other models tested are
either insensitive to HDACi or show sensitivity to Class I inhibitors
but not to Class II.
Similarities between models with respect to their
response to activating compounds
The relationship between models based on the ability of
compounds to activate latent HIV within each model was
investigated by hierarchical clustering and heatmap visualization
(Figures 2A and 2B). Two comparisons were performed. First, all
the cell models for which data was available for all compounds and
at all concentrations were compared (Figure 2A). This comparison
excluded the patient cell outgrowth assay for which data for only
certain concentrations of activators were available. In the second
comparison, all models were included but only those concentra-
tions that were universally tested were included (Figure 2B). In
both comparisons, reactivation values obtained with PHA at
10 mg/ml were used as a reference, to which all other reactivation
values were normalized to.
Both comparisons yielded strikingly similar results. Three
significant clusters of models were identified, with one robust
outlier, the Spina model. The Lewin and J-Lat 5A8 clustered very
close in both comparisons (Figures 2A and 2B), with the patient
cell assay/QVOA being the next closest to those two (Figure 2B).
Therefore, the first subcluster is defined by the Lewin, J-Lat-5A8
and QVOA models. The second subcluster is defined by the
Planelles and Siliciano models, closest to each other, and the
Greene model. The first two subclusters have a close association
with each other, that separates them from the three remaining J-
Lat clones (8.4, 6.3 and 11.1), which form the third and more
distant subcluster.
This clustering conforms to what would be expected biologically
with the majority of primary cell models clustering together and
the majority of cell line models clustering separately, with the
exception of J-Lat 5A8, which clusters among the primary models.
In addition, this clustering pattern was largely maintained when
the QVOA data was included and a reduced compound set
analyzed (Figure 2B). Since all primary cell models clustered
together, this suggests that the resting phenotype of these models
compared with the proliferating phenotype of J-Lat cells may
influence the responsiveness to different agents. The QVOA
model appears to cluster robustly with the Lewin model and the J-
Lat 5A8, suggesting that these two models may represent the best
proxy currently available for the activation capabilities of
compounds when analyzing cells from HIV-infected subjects.
However, this interpretation should be treated with caution as the
clustering in Figure 2B, when the QVOA data was included, was
performed with a reduced compound set and may not be as robust
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as the analysis that included all compounds at all concentrations
(Figure 2A).
Similarities between activating compounds with respect
to their activity across models
The relationship of compounds to each other, based on their
ability to activate HIV across the different models, was also
investigated by hierarchical clustering and heatmap visualization
(Figures 2A and 2B). The first analysis (Figure 2A) revealed
that PMA+Ionomycin and, separately, aCD3+aCD28 antibody
stimulation represented treatments that were strong outliers. The
rest of the compounds then fell into one of two significant major
clusters. The first cluster contained the majority of the HDACi,
but also IL-7+IL-2 treatment, Ionomycin, and HMBA. The
second cluster contained all concentrations of the PKC activators
(i.e., prostratin, PMA and bryostatin) as well as PHA, TNF-a and
the 6 mM concentration of MRK-1. This pattern of compound
clustering was supported when data from the QVOA was included
and a reduced compound set analyzed (Figure 2B).
It is noteworthy that HMBA clustered interspersed with the
HDAC inhibitors, which suggests potential similarities in the
mechanism of action. The recent finding that the HDAC
inhibitor, SAHA, can release P-TEFb from the inhibitory 7SK
snRNP complex [70] provides a potential explanation for the close
clustering of HMBA and HDAC inhibitors. In fact, a provocative
finding in that study was that the viral reactivating ability of SAHA
did not correlate with histone H3 or tubulin acetylation but,
rather, with release of P-TEFb [70].
As shown in Figures 2A and 2B, the NFkB agonists PMA,
prostratin, bryostatin, PHA and TNF-a cluster together. This
result indicates that NFkB agonists consistently work as latency-
reversing drugs across the different models, and that NFkB may
play a central role in viral reactivation from latency, independent
of the model used. In agreement with that, PHA and PMA were
active in all the models tested.
In summary, the clustering of compounds based on their
activation of HIV across models conforms to what would be
expected biologically and validates the analytical approach utilized
in the current study.
Discussion
This study represents the first experimental comparison among
several broadly used HIV latency systems, including primary cell
models, transformed cell lines and patient-derived cells. To
establish these comparisons in an unbiased manner, we chose a
panel of known stimuli that were tested in parallel in the selected
cell models. The methodology was designed to circumvent
variations due to batch, formulation or concentration differences
in the compounds tested. To the extent possible, the duration of
exposure to each stimulus, the inclusion of appropriate controls
and the maximal-response stimulus were standardized as well.
PHA was the only stimulus that uniformly reactivated latent
viruses in all systems tested. Most T cells, whether transformed or
primary, express CD3e or CD2, both of which are triggered by
PHA. Unfortunately, the therapeutic potential of agonists of the
CD3/CD28/CD2 signaling pathway is uncertain, given the
plethora of undesirable side effects, including transient lympho-
penia, previously observed in patients treated with OKT3
antibodies [71,72]. PMA also reactivated viruses across models.
Responsiveness to PMA was roughly, although not exactly,
paralleled by responsiveness to the other PKC agonists tested,
prostratin and bryostatin. For example, patient cells were
responsive to PMA and prostratin, but not to bryostatin.
Differences may be explained by the repertoire of PKC isoforms
that is activated by each PKC agonist. This issue will require
further exploration, as it is likely that certain PKC isoforms may be
more involved than others in the reactivation of latent HIV. It is
also plausible that certain PKC isoforms may be able to mediate
viral activation with only minimal induction of cellular activation
and/or proliferation, which, if true, would clearly be desirable in
an eradication strategy.
The addition of Ionomycin to PMA generally provided an
enhancement of the activity observed with PMA alone, with the
exception of cells in the Spina model. This is intriguing, and
contrary to expectations. Ionomycin induces calcium influx, which
activates the calcineurin phosphatase that, in turn, activates
NFAT. A possible explanation for the loss of activity with
PMA+Ionomycin in the Spina model might be the onset of
apoptosis, due to a high level of stimulation. However, this was not
the case; increased cell death was not observed in these cultures
during testing. Virus reactivation in the Spina model was
measured by levels of tat mRNA transcription after 24 hrs.
following exposure to stimulus. In other studies, in which HIV
reactivation was tracked by production of soluble p24, virus
replication was detected readily 4–5 days after PMA+Ionomycin
stimulation (C.A.S., unpublished results). Because PMA+Ionomy-
cin stimulation delivers such strong and immediate cell activation
signals, it may be possible that at early time points, limited
‘‘signaling resources’’ in primary T cells could be redirected away
from the viral LTR and initiation of tat transcription [39].
Additional studies will be necessary to address this mechanistic
point.
The activities of cytokines are usually dependent on the
presence or absence of their respective receptors on the target
cells. TNF-a showed remarkable activity in several J-Lat clones
and in patient cells, but was inactive or had low (Lewin) to
moderate (Spina) activity in the primary cell models. As stated
above, the TNF-R was not found in cultured or fresh TCM.
Therefore, the high level of responsiveness in patient cells may
underlie upregulation of the receptor under the culture conditions
utilized, including perhaps the incubation with TNF-a itself. It will
be informative to ascertain whether such upregulation occurs, and
the specific conditions influencing it. This putative upregulation of
the TNF-R is potentially exciting because, if appropriately
targeted to cells in the latent reservoir, it would render cells
exquisitely responsive to TNF-a or an agonist thereof. Respon-
siveness to TNF-a clusters among PKC agonists (Figures 2A and
Figure 2. Heatmap visualization of the ability of each compound to activate HIV within each model when excluding (A) and
including (B) data from the QVOA model. A reduced set of compounds was analyzed in (B) since not every compound was run at every
concentration in the QVOA. The clustergram at the left of each heatmap reflects the relationships between compounds based on their ability to
activate HIV across compounds. Since cells in all models responded to PHA with high strength, ranking was normalized within each model to the
response to PHA at 10 mg/mL and, therefore, all models display in the heatmap the same relative responsiveness to this treatment. The clustergram
at the top of each heatmap reflects the relationship between each model based on their response to compounds. Clustergrams were created by
calculating Euclidean distances and then clustering distances using the average linkage method. The numbers at the nodes of clusters are AU p-
values where 95% represents a p-value cut-off of 0.05 and only values 95% or greater are depicted. Red cells in the heatmaps reflect HIV activation
whereas blue or blank cells indicate that the compound did not effectively activate HIV.
doi:10.1371/journal.ppat.1003834.g002
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2B), which likely reflects the fact that both types of stimuli
culminate in NFkB activation. However, in the analysis displayed
in Figure 2A, TNF-a clusters closest with MRK-1, an HDACi, at
6 mM.
HDAC inhibitors are the first drug class to be utilized in clinical
trials for HIV eradication and the results so far have been
promising [69] because intracellular increases in HIV transcrip-
tion were induced in vivo during SAHA treatment. Future deve-
lopment of HDAC inhibitors should be directed at ascertaining
which HDAC isoforms are more involved in maintaining HIV
latency, so that they can be specifically targeted.
In general, the Lewin model clustered closely with the J-Lat
5A8 cells and both of these clustered with the patient cell
outgrowth assay. However, one of the major differences between
both models pertains to responsiveness to the HDACi, MRK11,
which blocks Class II enzymes. Cells in the Lewin model
displayed very high sensitivity to all tested HDACi, and were the
only ones in this study to exhibit a substantial response to
MRK11. In contrast, patient cells in the outgrowth assay did not
respond to MRK 11. Three primary cell models, Greene,
Planelles and Siliciano, had extremely low or no sensitivity to
HDACi treatments. It is unclear what aspects of the biology of
the cells or the latent viruses in these models renders the latent
viruses so refractory to the effects of HDAC inhibition. As we
suggest below, the low levels of active P-TEFb components in
resting cells may constitute a major barrier to efficient transcrip-
tion, which may not be overcome simply by inhibition of
HDACs. Recent observations indicate that incubation of primary
resting cells with stimuli that induce P-TEFb allows the cells to
then become responsive to HDAC inhibition (Matija Peterlin,
UCSF; personal communication).
Cells in the Lewin and patient cell/QVOA models shared
responsiveness to HMBA, while most other models had very low
or no responsiveness to this agent. HMBA facilitates the
dissociation of P-TEFb from the 7SK snRNP complex and makes
P-TEFb more readily available to interact with Tat, and then to be
recruited to the TAR loop on nascent viral RNAs. This is an early
step in the transcriptional activation of the silent provirus and,
therefore, it is viewed as a ‘‘gate keeper’’ step. Recent reports
[18,70,73] have suggested that resting T cells contain very low
levels of cyclin T and phosphorylated CDK9, leading to the
hypothesis that the activity of the P-TEFb complex is inherently
low, and not controlled by recruitment to the inactive 7SK snRNP
complex. In view of these observations, Budhiraja et al. explained
the lack of responsiveness of cells in the Planelles model as a result
of the low levels of cyclin T and of CDK9 phosphorylation [73].
However, the previous model does not explain two of the observed
responses in the present studies. First, patient cells and those in the
Lewin model responded strongly to HMBA, while also being
quiescent. Future studies should be undertaken to test the levels of
P-TEFb in these model systems and examine the correlation
between levels of P-TEFb and sensitivity to HMBA. Second, J-Lat
cells seemed unresponsive to HMBA, while they would be
expected to have high levels of active P-TEFb, given that they
are dividing cells. We speculate that P-TEFb is not limiting in J-
Lat cells, and that the rate-limiting step to active proviral
transcription is either at the transcription initiation level, prior to
the participation of Tat, or downstream of P-TEFb recruitment. A
plausible mechanism for the lack of activity of HMBA in J-Lat cells
is through transcriptional interference imposed by a proximal
cellular promoter, as was shown for certain J-Lat clones, including
J-Lat 6.3 and 8.4 [74].
Ionomycin was a poor inducer of reactivation in all primary cell
models and patient cells, and had no detectable activity in the J-
Lat cells. Calcium influx is necessary for activation of the NFAT
transcription factor, but is not sufficient by itself for optimal viral
reactivation. It appears that the full effect of NFAT on HIV
reactivation, at least in cultured TCM, requires an additional signal
provided by LCK activation [15].
PKC agonists were generally potent reactivators in most
models tested here. Bryostatin is of particular interest because it
stands as the only PKC agonist that is FDA approved and,
consequently, data on its pharmacokinetics and toxicity in
humans are available [75,76]. Bryostatin has been tested in
clinical trials for cancer and Alzheimer’s disease [75,76]. In
addition, bryostatin was shown to synergize with the HDACi,
valproic acid, in reactivation of latent HIV in a J-Lat model [76].
Although bryostatins are emerging as potential therapeutics for
HIV eradication, they typically induce cellular activation,
proliferation and secretion of pro-inflammatory cytokines. Thus,
future research will need to identify analogs with diminished
capacity to induce such undesirable cellular effects, while
preserving the ability to reactivate latent HIV.
No single experimental system of HIV latency completely
recapitulated responsiveness to all types of stimuli tested here. The
Lewin in vitro model displayed the broadest responsiveness.
Similarities between responsiveness of patient-derived cells and
the Lewin model cells were observed more frequently than with
any other model. However, several notable differences separated
the previous two models. These were: the high responsiveness of
the Lewin model to MRK-11 and bryostatin, which contrasted
with the lack of responsiveness of patient cells; and the lack of
response of Lewin cells to aCD3/aCD28. The lack of respon-
siveness of the Lewin model cells to IL-2+IL-7 contrasted with the
high responsiveness of the Spina and Siliciano models. Therefore,
secondary screening of latency reversing drugs obtained through
high throughput systems could be accomplished by using a
combination of testing in the Lewin system plus a system that
shows complementary properties, such as the Spina or the
Siliciano models.
The site of proviral integration can modulate the levels of viral
transcription and has been proposed as a mechanism to explain
latency [77,78]. Specifically, integration in the vicinity of actively
transcribed cellular genes can lead to transcriptional interference
effects [74,79,80]. The present study did not attempt to analyze
the influence of integration on proviral latency status. However, in
a separate study [81], the influence of host cell gene transcription
on proviral latency was analyzed and compared for five different
models of latency including the Siliciano [17] and Planelles [15]
models, a Jurkat model with polyclonal integration [78], infection
of primary resting CD4+ T cells [82], and infection of primary
activated CD4+ T cells [82]. When the influence of positioning in
the chromosome (regardless of orientation) was examined,
proviruses integrated in nearby positions shared the same latency
status more often than predicted by chance. However, this trend
was only statistically significant when comparing proviruses within
each model, but not when comparing proviruses across models.
This was interpreted by the authors to mean that local
chromosomal features affecting latency are model-specific. Re-
garding proviral orientation with respect to cellular genes, the
Siliciano model exhibited a modest, but statistically significant
preference for latent proviruses to be in the same orientation as
proximal cellular genes, confirming a previous report [80]. In
contrast, the other models exhibited no statistically significant
deviation from 50% of latent integrations being in the same
orientation as cellular genes.
Rational design of drugs to target HIV latency is not possible at
the moment, because we do not have precise knowledge of all the
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cellular factors and activation pathways that impact viral
transcription, leading to productive replication. A second obstacle
to rational drug design for viral eradication lies in the notion that
while the desired compound should trigger HIV reactivation, it
should induce minimal or no cellular activation/proliferation.
Therefore, drug screening studies should include an evaluation of
the ability of candidate compounds to induce expression of cellular
activation markers and proliferation.
Methods
Ethics statement
Studies involving human peripheral blood mononuclear cells
were conducted at the following institutions, and approved by the
respective internal boards as indicated:
University of California San Diego and the Veterans
Administration San Diego Healthcare System. This project
was reviewed and approved by the IRB of the Human Research
Protections Program of the University of California San Diego
(protocol #111173, 8/16/2012). Only adult subjects were
recruited into the study and they provided written informed
consent.
Monash University and Alfred Hospital. This project was
approved by the Monash University Human Research Ethics
Committee, project number 2012000032, Chief investigator Prof
Sharon Lewin. Date of approval, 16 January 2012.
University of North Carolina at Chapel Hill. The human
studies protocol was reviewed and approved by the Biomedical
institutional review board of UNC Chapel Hill. All adult subjects
provided written informed consent. University of Utah. Our
studies used blood purchased from the American Red Cross
without subject identifiers. Therefore, the University of Utah
Internal Review Board considered our work on this project
exempt from further protocol review and approval.
University of California San Francisco and Gladstone
Institute of Virology. Since blood was purchased from the
blood bank without subject identifiers, the UCSF Committee on
Human Research considered our work on this project exempt
from further protocol review and approval.
Johns Hopkins University School of Medicine. Blood was
obtained from healthy donors through a protocol approved by the
Johns Hopkins University School of Medicine Internal Review
Board #4. All study subjects provided written informed consent
prior to participation in the study.
Cell Models of HIV Latency
Greene Model, primary T cells. Healthy PBMCs were
isolated from leukoreduction system chambers (Trima Accel
System, Terumo BCT, Inc.) by Ficoll-Hypaque density gradient
centrifugation. Total CD4+ T cells were immediately isolated by
negative selection using EasySep Human CD4+ T Cell Enrich-
ment Kit (Stemcell Technologies). Isolated CD4+ T cells were
plated at a density of 16106 cells per well in a 96-well v-bottom
plate at a volume of 200 mL RPMI containing 10% FCS. Cells
were spinoculated with 100 ng (p24Gag) of NL4-3-Luciferase at
2,500 rpm for 2 h at 37uC. After spinoculation cells were
resuspended at a cell density of 16106 cells/mL in RPMI and
10% FCS containing 5 mM saquinavir mesylate (Sigma-Aldrich)
and incubated at 37uC for 72 h. Infected cells were then plated at
16106 cells/well in a 96-well flat-bottom plate in 200 mL RPMI
and 10% FCS containing 30 mM raltegravir (Santa Cruz
Biotechnology). The compounds to be tested were immediately
added at the indicated concentrations, and cells were incubated at
37uC. To analyze these samples, cells were washed with PBS and
lysed in Glo Lysis Buffer (Promega). Luciferase activity was
quantified using a BD Monolight Luminometer after mixing
50 mL of lysate with 50 mL of substrate (Luciferase Assay System,
Promega). Relative light units were normalized to protein content
determined by BCA assay (Pierce). All compounds were tested
with cells from 3 different donors and triplicate samples per assay.
When maximal stimulation was used, cell viability was over 75%
as determined by flow cytometry.
Lewin Model, primary T cells. Peripheral blood mononu-
clear cells (PBMC) were isolated from buffy coats obtained from
the Australian Red Cross Blood Service (Southbank, Australia).
Latently infected resting CD4+ T cells were prepared and
reactivated with a panel of agents, as previously described with
modifications [21,24]. Briefly, resting CD4+ T cells were isolated,
rested in culture 24 hours, incubated with the chemokine CCL19
at 29 nM (R&D, Minneapolis, MN) a further 24 hours and then
infected with the CXCR4 using virus HIV-1 NL4-3 at 0.5–1 CPM
reverse transcriptase activity per cell for 2 hours. Cells were
washed and cultured in RF10 and 1 IU/ml IL-2 for 4 days to
establish latency. Establishment of latency was confirmed by
detecting integrated HIV DNA using a nested Alu-LTR PCR [83]
and limited or no production of reverse transcriptase (RT) in cell
culture supernatant. To induce virus production, CCL19-treated
latently infected CD4+ T-cells were plated at 0.36106 cells/well in
a 96-well plate on day 4 post infection and incubated with the test
compounds. PHA-activated, CD8-depleted feeder PBMC were
added 24 hours after the activating stimulus at a ratio of 2 feeders
per T cell to amplify virus replication, as previously reported [46].
A half media change was performed 3 days post activation. Virus
production was measured in supernatant by quantification of RT
production at 5 days post activation. All compounds were tested
with cells from 4 different donors and triplicate repeats per assay.
Routinely, prior to stimulation in this assay, viability was greater
than 80%. Viability was not assessed at later time points due to the
addition of feeder cells.
Margolis, patient cells/viral outgrowth assay
(QVOA). For experiments using primary cells obtained from
HIV-infected, ART-treated, aviremic patients, outgrowth assays
were performed, as described previously [22]. Lymphocytes were
obtained by continuous-flow leukapheresis from HIV-infected
volunteers receiving stable ART with plasma HIV-1 RNA less
than 50 copies/ml and a CD4+ T cell count of more than 300
cells/ml. Patient cells were incubated with compounds for
24 hours to disrupt latency; the exception to this was combined
signaling with IL-2 and IL-7, which was maintained in cultures for
the first 2 days of the assay. Following this initial incubation, the
patient cells were plated in replicate dilutions and stimulated with
PHA-L, allogeneic irradiated PBMC from a sero-negative donor,
and rIL-2. CD8-depleted PBMC, collected from the same HIV
sero-negative donor, were added to culture at regular intervals.
Assays were carried out to 15 days of co-culture, at which time
soluble HIV p24 Gag antigen was measured by ELISA; any
cultures with detectable levels of p24 were deemed to be
potentially positive. Cultures were continued to day 19, and only
cultures that maintained an equivalent or greater level of p24
antigen on day 19 as on day 15 were scored as positive. In
duplicate experiments, the same patient’s cells were tested using
cells from the same sero-negative donor. All compounds were
tested with cells from 3 different HIV-infected patients. To
minimize the effects of the variance of the assay and of the varied
frequency of resting cell infection on the response to a stimulus, the
results from the limiting dilution cultures from all 3 patients were
pooled to calculate one common IUPM value. The IUPM values
thus obtained were then normalized to that obtained with PHA
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incubation. Therefore, standard deviations for data in the QVOA
could not be calculated.
Planelles Model, cytokine-polarized primary T
cells. Latently infected primary T cells were generated, using
a published method [14,15]. Briefly, CD4+ T cells, with a naı̈ve
phenotype were isolated by negative selection from fresh
peripheral blood and exposed to aCD3 plus aCD28 antibody-
coated beads (Dynal, 1:1 bead:cell ratio) for 3 days, with the
addition of TGF-b (10 mg/mL) and aIL-4 (1 mg/mL) and aIL-12
(2 mg/mL) monoclonal antibodies. Cells were then cultured in
rIL-2 for an additional 4 days to derive a differentiated ‘‘non-
polarized’’ subset (NP), which is considered the in vitro equivalent
of TCM [14,25], characterized by expression of CCR7, CD27,
CD45RO and the IL-7 receptor (CD127). At this point, latent
infection was established through spinoculation with an infectious
HIV-1 clone, defective in env. This virus was produced by co-
transfection with an HIV-1 X4 env expression vector in 293T cells
(DHIV). At one week following infection, most productively
infected cells were lost through apoptosis, and only latently
infected and uninfected cells remained. To maintain viability, cells
were cultured with rIL-2 for the duration of the experiments.
Reactivation of HIV was measured by intracellular expression of
Gag (p24), using flow cytometry analysis. All compounds were
tested with cells from 4 different donors and triplicate repeats per
assay. Viability at the time of readout was between 69 and 94% for
all treatments.
Siliciano Model, Bcl-2 transduced primary T cells. The
model characteristics were described previously, in detail [17]. To
summarize, bulk primary CD4+T cells were isolated by positive
selection (MACS) from peripheral blood, and stimulated with
immobilized aCD3 antibody in microplates in the presence of
aCD28 antibody and rIL-2 (100 U/mL). After 3 days, the
activated cells were transduced with the lentiviral vector, EB-
FLV, for constitutive expression of Bcl-2, and then expanded in
culture with rIL-2 for an additional 3 days. The transduced cells
returned to a resting state after 3–4 weeks of culture in the absence
of any exogenous cytokines. At this point, viable cells were
recovered and re-stimulated with immobilized aCD3 antibo-
dy+rIL-2, as before. After 10–12 days, the Bcl-2 transduced cells
were infected with the HIV reporter construct NL4-3-D6-drEGFP
(Denv; mutated gag, vif, vpr, vpu, nef) packaged in trans with X4-
tropic HIV-1 Env. The infected cells were cultured with rIL-2 for
3 days, and then maintained for at least 4 weeks in the absence of
exogenous cytokines. To recover latently infected CD4 cells, the
GFP-negative portion of the culture was purified by flow
cytometry sorting. The isolated cells had a predominant quiescent
cell phenotype (G0/1a) that is representative of effector memory T
cells (TEM), with expression of CD45RO
+RAdim/CCR72/
CD25dim [17]. Virus reactivation was measured by expression of
GFP, using flow cytometry analysis. All compounds were tested
with cells from 3 different donors and duplicate samples per assay.
After exposure to the test compounds, the cell viability at the time
of assay harvest was between 70–84% for all conditions, except for
the following treatments: highest PHA concentration, 41%;
highest concentration of all HDACi, 51–62%; Ionomycin, 63%.
Spina Model, primary T cells. Primary CD4+T cells were
isolated by negative selection (RosetteSep) from peripheral blood.
A portion of the cells was maintained in culture, without
stimulation, for 4 days. Another cell aliquot was stained with
CFSE dye, infected with replication-competent NL4-3, and
cultured in microplates with immobilized aCD3 and aCD28
antibodies to induce cell proliferation and productive HIV
replication [27]. After 4 days of culture, the CFSE-stained,
infected and proliferating cells were removed from the aCD3/
aCD28 stimulus and mixed with the unstimulated, uninfected
autologous CD4 cells at a ratio of 1:4. The co-culture was
maintained for 3 days with the addition of exogenous rIL-2 (5
U/mL). On day 7, the non-dividing ‘‘bystander cells’’ were
isolated from co-culture by flow cytometry sorting, and gating on
the small undivided, CFSE-negative subpopulation (FSC vs.
CFSE). The recovered infected bystander cells (90–95% viable)
were cultured in fresh medium, in the absence of any exogenous
cytokines, for 2 additional days, before being used in subsequent
experiments. HIV reactivation was performed in the presence of
the integrase inhibitor, raltegravir (0.1 mM) to exclude any
contribution from unintegrated virus. The latently infected
population ranged from 1 to 12% of cells containing integrated
HIV DNA [84], depending on the cell donor, and 0.5–5% of cells
with replication competent provirus that is inducible following
maximal stimulation with immobilized aCD3/aCD28 antibodies,
as measured by expression of intracellular Gag. Reactivation of
HIV was measured by RT-qPCR quantification of cell-associated
tat RNA and normalization to number tat copies per 108 copies
18S RNA. All compounds were tested with cells from 3 different
donors and duplicate repeats per assay. After exposure to the test
compounds, the cell viability at the time of assay harvest was
between 75–96% for all conditions.
Panel of Cell Stimuli
The test compounds, listed in Table 2, were obtained, and
stocks prepared and distributed centrally to each of the
participating laboratories by the CARE Pharmacology Core of
the University of North Carolina. The compounds were tested in
each cell model at the following final concentrations: aCD3/
aCD28-conjugated beads (Dynal) at 1:1 bead:cell ratio; PHA-M
(Sigma) at 1.1, 3.3, 10 mg/mL; PMA (Sigma) at 2 nM for primary
T cells, 16 nM for J-Lat cells; Ionomycin (Sigma) at 0.5 mM;
prostratin (LC Laboratories) at 0.3, 1, 3 mM; bryostatin (provided
by the National Cancer Institute) at 10, 33, 100 nM; SAHA/
vorinostat (Merck) at 0.11, 0.33, 1 mM; MRK-1 (class I HDACi,
Merck) at 0.67, 2, 6 mM; MRK-11 (class II HDACi, Merck) at 3,
10, 30 mM; HMBA (Sigma) at 0.3, 1, 3 mM; TNF-a (Peprotech) at
10 ng/mL; IL-2 (Peprotech) at 30 IU/mL; IL-7 (Peprotech) at
50 ng/ml. IL-2, IL-7, TNF-a, and aCD3/aCD28 bead stocks
were prepared in RPMI culture medium; HMBA stock was
prepared in water. All the other compounds were prepared in
DMSO solvent. Unless otherwise specified, each cell model tested
and the HIV outgrowth assay included the controls: untreated
(base culture medium), 0.1% DMSO, 0.5% DMSO (specific to
10 mg/mL PHA). The exposure time of cells to compounds was
standardized across the models to 24 hrs., except for PHA
(48 hrs.), aCD3/aCD28 beads (48–72 hrs.), and IL-2+IL-7 (5
days). The timing of assay read-outs for HIV reactivation was
specific to each model system, dependent on unique cellular and
viral characteristics.
Data normalization, heatmap visualization and clustering
Initially any compound or any concentration of a compound
that was not used universally across all models was removed. The
untreated control, representing background activation, was
subtracted from each compound for each donor in each model.
Activation values for each compound were then averaged across
donors within each model and any activation resulting from the
DMSO condition was subtracted from those compounds that were
dissolved in DMSO. DMSO has structural similarity to HDAC
inhibitors, as some of these compounds were derived from DMSO
following the observation of DMSO effects on transformed cells
[85]. Average activation values for each compound were then
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normalized within each model by dividing by the average
activation value for the highest concentration of PHA used so
that models could be compared to each other. Finally, examining
the distribution of average activation values across compounds
revealed right-skewed data for each model and thus a log10
transformation was performed. Constants were added to the
average activation value for each compound to account for
negative values prior to log10 transformation and to shift activation
values into a range that reflected their actual activation level.
An unsupervised approach was used to determine the relation-
ship between compounds based on their ability to activate HIV
across models and also between models based on their response to
compounds. Cluster 3.0 [86] was used for hierarchical clustering
of compounds and models such that distances were calculated
using the Euclidean based metric and then clustered using the
average linkage method. The results were visualized in a heatmap
using Java TreeView [87]. The statistical significance associated
with clustering was determined using pvclust [88] (R package),
which calculates approximately unbiased (AU) p-values that are
computed using multiscale bootstrap resampling such that 95%
equates to a p-value cut-off of 0.05. These normalization
procedures and hierarchical clustering approaches were per-
formed twice since not every compound was assessed at every
concentration in the QVOA model. Specifically, the were
performed once using a complete list of compounds but without
data from the QVOA and a second time with a subset of
compounds but now with the inclusion of data from the QVOA.
TNF receptor surface analysis
TNFR surface expression was determined using anti-human
TNFRI-APC (R&D Systems, Minneapolis, MN). Briefly, 16105
cells were incubated with 1:100 anti-human TNFRI-APC in
100 ml of PBS/3%FBS Buffer during 30 min at 4uC followed by
flow cytometric analysis in a BD FacsCanto II flow cytometer
using the FACSDiva software (Becton Dickinson, Mountain View,
CA). Data was analyzed with FlowJo (TreeStar Inc., Ashland,
OR).
Supporting Information
Figure S1 Levels of HIV induction are plotted for each stimulus
tested in each cell model. Within each model, results have been
normalized to the maximal response of a positive control stimulus
(e.g. aCD3/aCD28, PHA, or PMA+Io). The highest level of
response for each stimulus is shown, independent of the stimulus
concentration associated with the response. Positive responses are
rounded to the nearest decile percentage. Open bars indicate a
response below 5%.
(TIFF)
Figure S2 TNF-a receptor is not expressed in freshly isolated
memory CD4+ cells and is extremely low in cultured central
memory cells. Gray curves and black lines represent cells stained
with isotype control and TNFR antibody, respectively. J-Lat clone
10.6 was used as a positive control.
(TIFF)
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